Compound 1 had no significant effect on cell viability in any of the three breast cancer cell lines tested, including TNBC cell lines (BT-549 and MDA-MB-231) and the HER2+ breast cancer cell line, SK-BR-3 (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.